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Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically 
implementable tools able to precisely and non-invasively identify patients that can either be 
safely removed from treatment pathways, or those requiring further follow up.  Our objectives 
were to develop a multivariable risk prediction model through the integration of clinical, urine-
derived cell-free mRNA (cf-RNA) and urine cell DNA methylation data capable of non-
invasively detecting significant prostate cancer in biopsy naïve patients. 
Methods: 
Post-digital rectal examination urine samples previously analysed separately for both cellular 
methylation and cf-RNA expression within the Movember GAP1 urine biomarker cohort were 
selected for a fully integrated analysis (n = 207). A robust feature selection framework, based on 
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bootstrap resampling and permutation was utilised to find the optimal combination of clinical 
and urinary markers in a random forest model, deemed ExoMeth. Out-of-bag-predictions from 
ExoMeth were used for diagnostic evaluation in men with a clinical suspicion of prostate cancer 
(PSA 4 ng/mL, adverse DRE, age, or lower urinary tract symptoms). 
Results: 
As ExoMeth Risk Score (range 0-1) increased, the likelihood of high-grade disease being 
detected on biopsy was significantly greater (OR = 2.04 per 0.1 ExoMeth increase, 95% CI: 1.78 
- 2.35). On an initial TRUS biopsy, ExoMeth accurately predicted the presence of Gleason score 
3+4, AUC = 0.89 (95% CI: 0.84 - 0.93) and was additionally capable of detecting any cancer 
on biopsy, AUC = 0.91 (95% CI: 0.87 - 0.95). Application of ExoMeth provided a net benefit 
over current standards of care and has the potential to reduce unnecessary biopsies by 66% when 
a risk threshold of 0.25 is accepted. 
Conclusion: 
Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability 
than either method in isolation, providing superior predictive ability of biopsy outcomes. 
ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in 
substantial changes to how patients suspected of harbouring prostate cancer are diagnosed. 
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Introduction 
Prostate cancer exhibits extreme clinical heterogeneity; 10-year survival rates following 
diagnosis approach 84%, yet prostate cancer is still responsible for 13% of all cancer deaths in 
men in the UK (1). Coupled with the high rates of diagnosis, prostate cancer is more often a 
disease that men die with rather than from. This illustrates the need for clinically implementable 
tools able to selectively identify those men that can be safely removed from treatment pathways 
without missing those men harbouring disease that requires intervention. 
An opportune point to intervene or supplement current clinical practices would be prior to an 
initial biopsy in men suspected of having prostate cancer, reducing costs to men, healthcare 
systems and providers alike. In current clinical practice men are selected for further 
investigations for prostate cancer if they have an elevated PSA (≥4 ng/mL) and an adverse 
finding on digital rectal examination (DRE) or lower urinary tract symptoms; other factors such 
as age and ethnicity are also considered (2–4). However, the rates of negative biopsies in men 
with a clinical suspicion of prostate cancer are overwhelming; a recent population-level study of 
419,582 men from Martin et al observed that 60% of all biopsies in the control arm of the 
Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) were negative for prostate 
cancer (5), similar to the rates observed by Donovan et al as part of the ProtecT trial (6). Needle 
biopsy is invasive, and not without complications: 44% of patients report pain, and detection of 
clinically insignificant disease can result in years of monitoring, causing patients undue stress 
(4). Multiparametric MRI (MP-MRI) has been developed as a triage tool to reduce the rates of 
negative biopsy and its use has become increasingly widespread since its validation (7). 
However, MP-MRI is relatively expensive and has shown a high rate of inter-operator and inter-
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machine variability, leading to mpMRI missing up to 28% of clinically significant diseases in 
practice (4,8–10). 
The interconnected nature of the male urological system makes it an ideal candidate for liquid 
biopsy and non-invasive biomarkers for prostate cancer. There is sizeable interest in the 
development of such non-invasive tests and classifiers capable of reducing the rates of initial 
biopsy in men, whilst retaining the sensitivity to detect aggressive disease. Single-gene or 
expression panels of few genes, such as the PCA3 (11), SelectMDx (12), ExoDx 
Prostate(IntelliScore) (13) tests have published promising results to date for the non-invasive 
detection of significant disease (Gleason score (Gs) ≥7). Similarly, several urine methylation 
panels have been developed; the ProCUrE assay from Zhao et al quantifies the methylation of 
HOXD4 and GSTP1 for the detection of CAPRA score 3 – 10 disease (14), whilst Brikun et al 
assessed the binary presence/absence of CpG island methylation associated with 18 genes to 
predict the presence of any prostate cancer on biopsy (15). However, these biomarker panels 
have yet to be widely implemented in clinical settings, and none are currently recommended 
within the NICE guidelines (4), suggesting that improvements are required. Other studies have 
aimed to detect the most aggressive cancers by utilising tissue samples taken at the time of 
biopsy, resulting in moderate success and wider clinical adoption (16–18). However, due to their 
proposed implementation within current clinical pathways, these tests may not take into 
consideration the considerable economic, psychological and societal costs of unnecessarily 
subjecting men with low volume, indolent disease to biopsy (19–21). 
In 2012, the Movember Global Action Plan 1 (GAP1) initiative was launched, a collaborative 
effort between multiple institutes focusing on prostate cancer biomarkers in urine, plasma, serum 
and extracellular vesicles. The prime aim of the GAP1 initiative was to develop a multi-modal 
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urine biomarker panel for the discrimination of disease state. The authors have previously 
published analyses from two of the GAP1 studies that measured differing molecular aspects 
within urine; epiCaPture assayed hypermethylation of urinary cell DNA (22), and PUR assessed 
transcript levels in cell-free extracellular vesicle mRNA (cf-RNA) using NanoString (23). Both 
of these tests were able to discriminate some level of clinically significant disease and exhibited 
differing characteristics; where epiCaPture was well suited to detecting the highest grade disease 
(Gleason score ≥8), PUR was better matched to the deconvolution of lower risk and indolent 
disease, as detailed by its prognostic ability in active surveillance use. With a suitable overlap in 
the numbers of patient samples analysed by both methods, we hypothesised that these two 
methods could be complementary, and the integration of both datasets could result in a more 
holistic model with predictive ability greater than the sum of its parts, able to encapsulate the 
clinical heterogeneity of prostate cancer and reach the levels of accuracy and utility required for 
widespread adoption. In this study, we report the diagnostic accuracy of such an integrated 
model, determined by the ability to predict the presence of Gs ≥7 and Gs ≥4+3 disease on 
biopsy, both critical distinctions, where patients with Gs ≥ 7 are recommended radical therapy 
(4), whilst patients with Gs 4+3 have significantly worse outcomes than Gs 3+4 patients (24). 
Mindful that many cancer biomarkers fail to translate to the clinic, the development of the 
presented model has been carried out adhering to the transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis (TRIPOD) guidelines (25). 
 7 
Materials and Methods 
Patient population and characteristics 
The full Movember GAP1 urine cohort comprises of 1,257 first-catch post-DRE, pre-TRUS 
biopsy urine samples collected between 2009 and 2015 from urology clinics at multiple sites. 
Samples within the Movember cohort that were analysed for both methylation and cf-RNA were 
eligible for selection for model development in the current study (n = 207). 
Exclusion criteria for model development included a recent prostate biopsy or trans-urethral 
resection of the prostate (<6 weeks) and metastatic disease (confirmed by a positive bone-scan or 
PSA >100 ng/mL), resulting in a cohort of 197 samples, deemed the ExoMeth cohort. The 
samples analysed in the ExoMeth cohort were collected from the Norfolk and Norwich 
University Hospital (NNUH, Norwich, UK, n = 181) and St. James’s Hospital (SJH, Dublin, 
Republic of Ireland, n = 16). 
Sample Processing and analysis 
Urine samples were processed according to the Movember GAP1 standard operating procedure 
(Supplementary Methods). Hypermethylation at the 5’-regulatory regions of six genes (GSTP1, 
SFRP2, IGFBP3, IGFBP7, APC and PTSG2) in urinary cell-pellet DNA was assessed using 
quantitative methylation-specific PCR as described by O’Reilly et al (2019). Cell-free mRNA 
was isolated and quantified from urinary extracellular vesicles using NanoString technology, 
with 167 gene-probes (Supplementary Table 1), as described in Connell et al (2019), with the 
modification that NanoString data were normalised according to NanoString guidelines using 
NanoString internal positive controls, and log2 transformed. Clinical variables that were 
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considered are serum PSA, age at sample collection, DRE impression and urine volume 
collected. 
Statistical Analysis 
All analyses, model construction and data preparation were undertaken in R version 3.5.3 (26), 
and unless otherwise stated, utilised base R and default parameters.. 
Feature Selection 
In total 177 variables available for prediction (cf-RNA (n = 167), methylation (n = 6) and clinical 
variables (n = 4). For full list see Supplementary Data), making feature selection a key task for 
minimising model overfitting and increasing the robustness of trained models. To avoid dataset-
specific features being positively selected (27)we implemented a robust feature selection 
workflow utilising the Boruta algorithm (28) and bootstrap resampling. Boruta is a random 
forest-based algorithm that iteratively compares feature importance against random predictors, 
deemed “shadow features”. Features that perform significantly worse compared to the maximally 
performing shadow feature at each permutation, (p ≤ 0.01, calculated by Z-score difference in 
mean accuracy decrease) are consecutively dropped until only confirmed, stable features remain. 
Boruta was applied on 1,000 datasets generated by resampling with replacement. Features were 
only positively selected for model construction when confirmed as stable features in ≥ 90% of 
resampled Boruta runs. 
Additional methylation information from four genes (HOXD3, TGF2, KLK10 and TBX15), was 
available for a subset of the ExoMeth cohort from previous analyses by Zhao et al (n = 144), 
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however these genes did not add additional information in preliminary analysis and were not 
included in further analyses (data not shown). 
Comparator Models 
To evaluate potential clinical utility, additional models were trained as comparators using subsets 
of the available variables across the patient population: a clinical standard of care (SoC) model 
was trained by incorporating age, PSA, T-staging and clinician DRE impression; a model using 
only the available DNA methylation probes (Methylation, n = 6); and a model only using 
NanoString gene-probe information (ExoRNA, n = 167). The fully integrated ExoMeth model 
was trained by incorporating information from all of the above variables (n = 177). Each set of 
variables for comparator models were independently selected via the bootstrapped Boruta feature 
selection process described above to select the most optimal subset of variables possible for each 
predictive model. 
Model Construction 
All models were trained via the random forest algorithm (29), using the randomForest package 
(30) with default parameters except for: resampling without replacement and 401 trees being 
grown per model. Risk scores from trained models are presented as the out-of-bag predictions; 
the aggregated outputs from decision trees within the forest where the sample in question has not 
been included within the resampled dataset (29). Bootstrap resamples were identical for feature 
selection and model training for all models and used the same random seed. 
Models were trained on a modified continuous label, based by binning samples on biopsy 
outcome and constructed as follows: samples were scored on a continuous scale (range: 0 – 1) 
according to Gleason score: where no evidence of cancer on biopsy are scored 0, patients with 
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predominantly Gleason pattern 3 disease are assigned 0.5 and predominantly Gleason 4 (or 5) are 
assigned to 1. Further treating this label as a continuous variable recognises that two patients 
with the same Gleason scored TRUS-biopsy detected cancer may not share the exact same 
proportions of tumour pattern, or overall disease burden within their prostate. This scale is solely 
used for model training and is not represented in any clinical endpoint measurements, or for 
determining predictive ability and clinical utility. 
Statistical evaluation of model predictivity 
Area Under the Receiver-Operator Characteristic curve (AUC) metrics were produced using the 
package (31), with confidence intervals calculated via 1,000 stratified bootstrap resamples. 
Density plots of model risk scores, and all other plots were created using the ggplot2 package 
(32). Cumming estimation plots and calculations were produced using the dabestr package (33) 
and 1,000 bootstrap resamples were used to visualise robust effect size estimates of model 
predictions. 
Decision curve analysis (DCA) (34) examined the potential net benefit of using the developed 
comparator models in the clinic. Standardised net benefit (sNB) was calculated with the rmda 
package (35) and presented throughout our decision curve analyses as it is a more directly 
interpretable metric compared to net benefit (36). In order to ensure DCA was representative of a 
more general population, the prevalence of Gleason scores within the ExoMeth cohort were 
adjusted via bootstrap resampling to match those observed in a population of 219,439 men that 
were in the control arm of the Cluster Randomised Trial of PSA Testing for Prostate Cancer 
(CAP) Trial (37), as described in Connell et al (2019). Briefly, of the biopsied men within this 
CAP cohort, 23.6% were Gs 6, 8.7% Gs 7 and 7.1% Gs ≥8, with 60.6% of biopsies showing no 
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evidence of cancer. These ratios were used to perform stratified bootstrap sampling with 
replacement of the Movember cohort to produce a “new” dataset of 197 samples with risk scores 
from each comparator model. sNB was then calculated for this resampled dataset, and the 
process repeated for a total of 1,000 resamples with replacement. The mean sNB for each risk 
score and the “treat-all” options over all iterations were used to produce the presented figures to 
account for variance in resampling. Net reduction in biopsies, based on the adoption of models 
versus the default treatment option of undertaking biopsy in all men with PSA ≥ 4 ng/mL was 
calculated as: 




Where the decision threshold (Threshold) is determined by accepted patient/clinician risk (34). 
For example, a clinician may accept up to a 25% perceived risk of cancer before recommending 
biopsy to a patient, equating to a decision threshold of 0.25. 
Results 
The ExoMeth development cohort 
Linked methylation and transcriptomic data were available for 197 patients within the Movember 
GAP1 cohort, with the majority originating from the NNUH and forming the ExoMeth 
development cohort (Table 1). The proportion of Gleason ≥7 disease in the ExoMeth cohort was 
49%. 
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Feature selection and model development 
Using a robust feature selection framework four models were produced in total; a standard of 
care (SoC) model using only clinical information (age and PSA), a model using only methylation 
data (Methylation, 6 genes), a model using only cf-RNA information (ExoRNA, 12 gene-probes) 
and the integrated model, deemed ExoMeth (16 variables) (Table 2). The ExoMeth model is a 
multivariable risk prediction model incorporating clinical, methylation and cf-RNA variables. 
When the resampling strategy was applied for feature reduction using Boruta, 16 variables were 
selected for the ExoMeth model. Each of the retained variables were positively selected in every 
resample and notably included information from clinical, methylation and cf-RNA variables 
(Figure 1). Full resample-derived Boruta variable importances for the SoC, Methylation and 
ExoRNA comparator models can be seen in Supplementary Figures 1 – 3, respectively. 
In the SoC comparator model only PSA and age were selected as important predictors. All 
methylation probes were selected as important in both the independent Methylation model and 
the ExoMeth models (Table 2). 12 NanoString gene-probes were selected for the NanoString 
model, notably containing both variants of the ERG gene-probe and TMPRSS2/ERG fusion gene-
probe, alongside PCA3. All features within the ExoMeth model were also selected in one of the 
comparator models. 
ExoMeth predictive ability 
As ExoMeth Risk Score (range 0-1) increased, the likelihood of high-grade disease being 
detected on biopsy was significantly greater (Proportional odds ratio = 2.04per 0.1 ExoMeth 
increase, 95% CI: 1.78 - 2.35; ordinal logistic regression, Figure 2). The median ExoMeth risk 
score was 0.83 for metastatic patients (n = 10). These were excluded from model training and 
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can be considered as a positive control. One metastatic sample had a lower than expected 
ExoMeth score of 0.55: where no methylation was quantified for this sample, which may reflect 
a technical failure of the sample. 
ExoMeth was superior to all other models, returning an AUC of 0.89 (95% CI: 0.84 - 0.93) for 
Gleason ≥3+4 and 0.81 (95% CI: 0.75 - 0.87) for Gleason ≥4+3 (Table 3). As revealed by the 
distributions of risk scores and AUC, ExoMeth achieved a better discrimination of Gleason ≥ 
3+4 disease from other outcomes when compared to any of the other models (ExoMeth all p < 
0.01 bootstrap test, 1,000 resamples, Figure 3). The SoC model, whilst returning respectable 
AUCs, would misclassify more men with indolent disease as warranting further investigation 
than all other models (Figure 3A), for example, to classify 90% of Gleason 7 men correctly, an 
SoC risk score of 0.237 would misclassify 65% of men with less significant disease. The 
methylation comparator model improves upon SoC, by drawing the risk score distribution of Gs 
< 7 men into a more pronounced peak but featured a bimodal risk score distribution extending to 
higher-risk men; almost 50% of men with Gs ≥ 3+4 have risk scores equal to benign patients 
(Figure 3B). The opposite occurred in the NanoString comparator model exhibited a broad 
bimodal distribution for lower-risk men (Figure 3C). This discriminatory ability of the ExoMeth 
model over all comparators was improved when biopsy outcomes are considered as biopsy 
negative, Gleason 6 or 3+4, or Gleason ≥4+3 (Supplementary Figure 4). 
Resampling of ExoMeth predictions via estimation plots allowed for comparisons of mean 
ExoMeth signatures between groups (1,000 bias-corrected and accelerated bootstrap resamples, 
Figure 4). The mean ExoMeth differences between patients with no evidence of cancer were: 
Gleason 6 = 0.22 (95% CI: 0.14 – 0.30), Gleason 3+4 = 0.36 (95% CI: 0.28 – 0.42) and Gleason 
≥4+3 = 0.44 (95% CI: 0.37 – 0.51). Notably, there were no differences in ExoMeth risk 
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signatures of patients with a raised PSA but negative for cancer on biopsy and men with no 
evidence of cancer (mean difference = 0.03 (95% CI: 0.05 – 0.10), Figure 4, Supplementary 
Figure 5). 
Decision curve analysis examined the net benefit of adopting ExoMeth in a population of 
patients suspected with prostate cancer and to have a PSA level suitable to trigger biopsy (≥ 4 
ng/mL). The biopsy of men based upon their ExoMeth risk score consistently provided a net 
benefit over current standards of care across all decision thresholds examined and was the most 
consistent amongst all comparator models across a range of clinically relevant endpoints for 
biopsy (Figure 5). Of the patients with Gs ≥ 7 disease, 95% had an ExoMeth risk score ≥ 0.283. 
At a decision threshold of 0.25, ExoMeth could result in up to 66% fewer unnecessary biopsies 
of men presenting with a suspicion of prostate cancer, without missing substantial numbers of 
men with aggressive disease, whilst if Gleason ≥ 4+3 were considered the threshold of clinical 
significance, the same decision threshold of 0.25 could save 79% of men from receiving an 
unnecessary biopsy (Figure 6). 
Discussion 
The accurate discrimination of disease state in men prior to a confirmatory initial biopsy would 
mark a significant development and impact large numbers of men suspected of harbouring 
prostate cancer. Up to 75% of men with a raised PSA (≥4 ng/mL) are negative for prostate 
cancer on biopsy (4,5,38). This has resulted in concentrated research efforts to address this 
problem non-invasively, and resulting in the development of several biomarker panels capable of 
detecting Gleason ≥3+4 disease with superior accuracy to current clinically implemented 
methods (11–13,23). However, in each of these examples, only a single quantification method or 
 15 
biological process is assayed and with the molecular heterogeneity of prostate cancer considered 
(39), a more holistic approach is necessary. 
It is becoming apparent from published data that urine can contain a wealth of useful cancer 
biomarkers within RNA, DNA, cell-free DNA, DNA methylation and proteins (14,22,23,40,41). 
However, the analyses presented here are, to the author’s knowledge, the first attempt to 
integrate such biomarker information within the same samples for the detection of prostate 
cancer prior to biopsy. There has recently been reported that a combination of miRNA and 
methylation markers can be used to predict outcome following radical prostatectomy (42). Our 
results show an improved diagnostic marker can be produced from the synergistic relationship of 
information derived from different urine fractions in men suspected to have prostate cancer. The 
methylation of six previously identified genes (22) was quantified via methylation specific 
qPCR, whilst the transcript levels of 167 cell-free mRNAs were quantified using NanoString 
technology. The final model integrating this information with serum PSA levels was deemed 
ExoMeth. Markers selected for the model include well known genes associated with prostate 
cancer and proven in other diagnostic tests, such as HOXC6 (12), PCA3 (11) and the 
TMPRSS2/ERG gene fusion (43). ExoMeth additionally incorporated GJB1 as the most 
important variable for predicting biopsy outcome. Whilst GJB1 is known to be a prognostic 
marker for favourable outcome in renal cancers, there is no current evidence of its use as a 
diagnostic biomarker in prostate cancer (44,45). 
ExoMeth was able to correctly predict the presence of significant prostate cancer on biopsy with 
an AUC of 0.89, representing a significant uplift when compared to other published tests (AUCs 
for Gs ≥7 : PUR = 0.77 (23), ProCUrE = 0.73 (14), ExoDX Prostate IntelliScore = 0.77 (13), 
SelectMDX = 0.78 (12), epiCaPture AUC = 0.73 (Gs ≥4+3) (22)). Furthermore, ExoMeth 
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resulted in accurate predictions even when serum PSA levels alone were inaccurate; where 
patients with a raised PSA but negative biopsy result possessed similar ExoMeth scores as 
clinically benign men, whilst still able to discriminate between Gleason grades (Figure 4). These 
are men that would be unnecessarily subjected to biopsy by current guidelines. Of the three 
patients with no evidence of cancer on biopsy with an ExoMeth risk score >0.55, two were 
positive for the TMPRSS2/ERG fusion transcript in NanoString analyses (data not shown), 
implying that PCa may have been missed and re-biopsy may be necessary (46). Future 
prospective studies plan to utilise template biopsy and more detailed information about each 
biopsy core to account for the ambiguity in TRUS biopsy estimation of Gleason score. 
Whilst every step has been taken to robustly develop ExoMeth to minimise potential overfitting 
and bias through extensive bootstrap resampling and the use of out-of-bag predictions, ExoMeth 
nonetheless was developed on a small dataset and requires validation in an independent cohort 
before its use a clinical marker can be considered. Additionally, as MP-MRI can misrepresent 
disease state in patients, even when rigorous protocols are implemented (7) the clinical utility of 
supplementing MP-MRI with ExoMeth needs to be assessed. For many men harbouring indolent 
prostate cancer, ExoMeth could greatly impact their experience of prostate cancer care when 
compared to current clinical pathways. 
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Figure Legends 
Figure 1. Boruta analysis of variables available for the training of the ExoMeth model. Variable 
importance was determined over 1,000 bootstrap resamples of the available data and the 
decision reached recorded at each resample. Colour indicates the proportion of the 1,000 
resamples a variable was confirmed to be important in. Variables confirmed in at least 90% of 
resamples were selected for predictive modelling. Those variables rejected in every single 
resample are not shown here, but the full list of inputs for all models can be seen in 
Supplementary Table 1. 
Figure 2. Waterfall plot of the ExoMeth risk score for each patient. Each coloured bar 
represents an individual patient’s calculated risk score and their true biopsy outcome, coloured 
according to Gleason score (Gs). Green - No evidence of cancer, Blue – Gs 6, Orange - Gs 3+4, 
Red - Gs ≥ 4+3. 
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Figure 3. Density plots detailing risk score distributions generated from four trained models. 
Models A to D were trained with different input variables; A - SoC clinical risk model, including 
Age and PSA, B - Methylation model, C -ExoRNA model and D - ExoMeth model, combining the 
predictors from all three previous models. The full list of variables in each model is available in 
Table 1. Fill colour shows the risk score distribution of patients with a significant biopsy 
outcome of Gs ≥ 3+4 (Orange) or Gs ≤ 6 (Blue). 
Figure 4. Cumming estimation plot of the ExoMeth risk signature. The top row details individual 
patients as points, separated according to Gleason score on the x-axis and risk score on the y-
axis. Points are coloured according to clinical risk category; NEC - No evidence of cancer, 
Raised PSA - Raised PSA with negative biopsy, L -D’Amico Low-Risk, I - D’Amico Intermediate 
Risk, H - D’Amico High-Risk. Gapped vertical lines detail the mean and standard deviation of 
each group’s risk scores. The lower panel shows the mean differences in risk score of each 
group, as compared to the NEC samples. Mean differences and 95% confidence interval are 
displayed as a point estimate and vertical bar respectively, using the sample density distributions 
calculated from a bias-corrected and accelerated bootstrap analysis from 1,000 resamples. 
Figure 5. Decision curve analysis (DCA) plots detailing the standardised net benefit (sNB) of 
adopting different risk models for aiding the decision to biopsy patients who present with a PSA 
≥ 4 ng/mL. The x-axis details the range of risk a clinician or patient may accept before deciding 
to biopsy. Panels show the sNB based upon the detection of varying levels of disease severity: A 
- detection of Gleason ≥ 4+3, B - detection of Gleason ≥ 3+4, C - any cancer; Blue- biopsy all 
patients with a PSA >4 ng/mL, Orange - biopsy patients according to the SOC model, Green - 
biopsy patients based on the methylation model, Purple - biopsy patients based on the 
NanoString model, Red - biopsy patients based on a the ExoMeth model. To assess the benefit of 
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adopting these risk models in a non-PSA screened population we used data available from the 
control arm of the CAP study (5). DCA curves were calculated from 1,000 bootstrap resamples 
of the available data to match the distribution of disease reported in the CAP trial population. 
Mean sNB from these resampled DCA results are plotted here. See Methods for full details. 
Figure 6. Net percentage reduction in biopsies, as calculated by DCA measuring the benefit of 
adopting different risk models for aiding the decision to biopsy patients who would otherwise 
undergo biopsy by current clinical guidelines. The x-axis details the range of accepted risk a 
clinician or patient may accept before deciding to biopsy. Panels show the reduction in biopsies 
per 100 patients based upon the detection of varying levels of disease severity: A - detection of 
Gleason ≥ 4+3, B - detection of Gleason ≥ 3+4 and C - any cancer. Coloured lines show 
differing comparator models; Blue- biopsy all patients with a PSA >3 ng/mL, Orange - biopsy 
patients by according the to the SoC model, Green - biopsy patients based on the methylation 
model, Purple - biopsy patients based on the ExoRNA model, Red - biopsy patients based on a 
the ExoMeth model. To assess the benefit of adopting these risk models in a non-PSA screened 
population we used data available from the control arm of the CAP study (5). DCA curves were 
calculated from 1,000 bootstrap resamples of the available data to match the distribution of 
disease reported in the CAP trial population. Mean sNB from these resampled DCA results are 
used to calculate the potentially reductions in biopsy rates here. See Methods for full details. 
 
 
